Proteomics meeting next month
Claire Morgan
Monday, 15 October 2007 10:56 UTC
There is a great line-up of talks at EuroSciCon’s ‘Proteomics: advances in biomarker discovery’ meeting on 23rd November 2007. Why not submit an abstract for presentation?
’’This meeting examines the use of proteomics in the identification of biomarkers using a variety of old, new and developing technologies’’, Meeting Chair – Dr Ayesha De Souza, St. George’s Hospital, London
Speakers include Dr Ashley Martin (CRUK Institute for Cancer Studies, University of Birmingham), Dr Robin Wait (Kennedy Institute of Rheumatology, Imperial College London), Dr Mark Weeks (Institute of Cancer), Professor Robert Rees (Department of Life Sciences, Nottingham Trent University), Dr Lynn Cawkwell (The University of Hull) and Dr Judit Nagy (Imperial College).
Book now by clicking here
Abstracts accepted for poster and oral presentations will also be published in the proceedings. There will be a prize for the best poster. Abstract guidelines can be found here
Updated 15 October 2007 10:56 UTC
-
Replies
-
This content has been removed by the forum moderators.
-
Just to say that there is a packed agenda for this event (see below) and we are offering Nature network readers 50% of their registration fee- just type in the code NETWORK during your online registration to get your discount
09:00 – 09:45 Registration – Tea/Coffee
09:45 – 10:00 Introduction by the Chair: Dr Ayesha De Souza
St. George’s, University of London, UK
10:00 – 10:30 Proteomic approaches to biomarker discovery and validation
Dr Ashley Martin, CRUK Institute for Cancer Studies, University of Birmingham, UK
There is a great need to discover and validate clinically use cancer biomarkers. It is widely accepted the early detection and treatment of cancer is one the most important factors for patient survival. However, the available biomarkers are neither sensitive nor specific enough to be relied upon for routine diagnosis. Technological advances in mass spectrometry have allowed the serum proteome to be scrutinized in more detail and these approaches have been applied to biomarker discovery for a range of cancer types. The methodologies and associated problems will be discussed.
10:30 – 11:00 Proteomic strategies for biomarker discovery in rheumatoid arthritis and osteoarthritis
Dr Robin Wait, Kennedy Institute of Rheumatology, Imperial College London, UK
11:00 – 11:15 Group photo
11:15 – 11:45 Morning Tea/Coffee and Poster Viewing
11:45 – 12:15 The use of proteomic technologies to searching for early biomarkers of pancreatic ductal adenocarcinoma
Dr Mark Weeks, Institute of Cancer, UK
Pancreatic cancer is the fourth leading cause of cancer – related deaths in the western world. It is difficult to detect early can only can be cured if it is found at an early stage. There is a real need to find non-invasive disease markers that will enable earlier intervention and improve patient prognosis. Urine is easily an obtainable body fluid that may be a source of cancer biomarkers. The application of proteomic techniques to screen the urine of patients for changes occurring at the molecular level could potentially revolutionise the detection and management of pancreatic cancer, thus saving valuable lives.
12:15 – 12:45 Cancer Biomarkers to predict clinical status and response to Immunotherapy
Professor Robert Rees, Department of Life Sciences Nottingham Trent University Nottingham, UK
12:45 – 13:15 Tour of the BioPark
13:15 – 14:30 Lunch and Poster Viewing
14:30 – 15:00 Proteomic approaches for the study of anticancer therapies
Dr Lynn Cawkwell, The University of Hull, UK
We are utilising a combined approach based on transcriptomic and proteomic methods to further our understanding of a range of anticancer therapies (chemotherapy, radiotherapy, hormone therapy, antiangiogenic therapies). To identify biomarkers associated with radiotherapy resistance we utilised complementary techniques including expression microarrays, antibody microarrays and 2DE/MALDI-ToF analysis. Putative biomarkers were validated using immunoblotting and real-time PCR.
15:30 – 16:00 A type 2 diabetes model investigated by proteomics and validated by the deltaDOT LFII technology
Dr Judit Nagy, Imperial College, London, UK
Type 2 diabetes (T2D), which develops when the body produces only a limited amount of insulin, or when the insulin that is produced does not function properly, termed ‘insulin resistance’. It is widely accepted that insulin binding to its receptor on target cells mediates downstream phosphorylation and activation of the insulin receptor substrate (IRS) family. Transgenic KO mice lacking IRS2 display many of the hallmarks of T2D in human subjects, which includes peripheral insulin resistance and a lack of compensatory ß-cell expansion. In order to further elucidate the protein expression alterations within the liver in response to T2D we compared the hepatic protein expression of livers from WT and IRS2
/mice. Proteomics data was validated using capillary electrophoresis on deltaDOT’s Peregrine.16:00 – 16:30 Abstracts
16:30 – 17:00 Chairman’s summing up & close.
About the speakers
Dr Ashley Martin, CRUK Institute for Cancer Studies, University of Birmingham
Dr Martin started his research looking into the regulation of glycerolipid biosynthesis in rat livers at the University of Nottingham with Prof David Brindley. When reports came out implicating glycerolipids as signalling intermediates this work became the main focus of Dr Martin’s research. After working on cell signalling with Prof. Wakelam at Birmingham and as a Senior Lecturer at the University of Wolverhampton Dr Martin set up the proteomic facility at the CRUK Institute for Cancer Studies at Birmingham University. The main focus of research in the group is cancer biomarker discovery using mass spectrometry based technologies.Dr Mark Weeks, Institute of Cancer, UK
After gaining a PhD from the University of kent I took a position at Ludwig institute for cancer Research as a postdoctoral research fellow. Work conducted at Ludwig centered on the use of proteomic technology to define differences induced by low file strength magnetic fileds in the yeast schizzosaccaromyces pombe. From the Ludwig I joined QMUL where I have used proteomic technology to look for biomarkers of pancreatic cancer in clinical urine samples. I have since moved on to the UCL cancer proteomics unit.Dr Judit Nagy, Imperial College, London, UK
Dr Judit M. Nagy, MRSC, is currently Research Scientist in Proteomics in the Institute of Biomedical Engineering at Imperial College. Apart from managing the high-throughput proteomics facility, she runs her own research group. Her main research programmes include the proteomic characterization of stem cells and the mapping of the insulin resistance pathway. In her previous job she was the Protein Analysis Core Facility Manager based in the Centre for Molecular Microbiology and Infection (CMMI) at Imperial College London. By nature of her job she has been collaborating on numerous projects within and outside of Imperial College.Dr Lynn Cawkwell, The University of Hull, UK
I gained a BSc (Hons) in Genetics and then worked as a Scientific Officer researching DNA repair at the Paterson Institute for Cancer Research before moving to Leeds University to pursue a PhD in molecular oncology. I joined the new Academic Department of Oncology, University of Hull as a Lecturer in 1999, establishing a program of cancer research covering Histology, Molecular Pathology, Molecular Genetics and Proteomics in the R&D Laboratory, Castle Hill Hospital. The focus is the study of anticancer therapies. I was promoted to Senior Lecturer in 2003 and established a multidisciplinary collaborative Cancer Biology Proteomics Group.Dr. Delmiro Fernandez-Reyes, National Institute for Medical Research, London, UK
Trained as a cinician I did a DPhil on basic science focused at the study of the molecular basis of severe malaria infections. After that I was awarded a MRC Special Training Fellowship in Bioinformatics during which I trained as a Computer Scientist focused in Statistical Machine Learning and its application in proteomic datasets. Recently I started running my independent research program at the MRC National Institute for Medical Research -
There a five places available at this meeting for only £50 each… To book, please enter the code proteome when registering online here
-
A report for this meeting is now available on www.eurosciconpodcasts.com . It has been written by Dr. Dr Matthew Cowan (Clinical Research Fellow,
Centre for Infection, Division of Cellular and Molecular Medicine, St George’s, University of London and his colleague Jaime Vera.In February another report for this meeting will be published in Expert Review of Proteomics.
-
The proceedings book for this meeting is now available. A paperback versoin only costs £25. If you were unable to be there on the day you can order it now by clicking on the link below:
http://www.lulu.com/content/1673145
-
A report from this meeting has been published in Expert Reviews in Proteomics.
The citation is as follows:
Expert Rev. Proteomics 5(1), 21-23 (2008)
For those of you working in this field we have three meetings this year that will interest you. Book now to avoid the early registration deadline;
Gene therapy – Systems and Applications
Friday, June 24, 2008. BioPark, Hertfordshire
The deadline for early registration is April 20th 2008.
For more information click herePCR Perfection: Insider tricks
Friday, October 3, 2008. BioPark, Hertfordshire
The deadline for early registration is July 20th 2008
For more information click hereProblems with Microarrays (and how to shoot them!) – A day filled with technical tips that didn’t make it to the manuals yet
Tuesday, November 04, 2008. BioPark, Hertfordshire
The deadline for early registration is August 20th 2008
For more information click hereWe hope to see you there!
-